CPC Comments on Health Canada’s Drug-Device Combination Products (DDCPs) Draft for Consultation Issue Identification Paper

On July 12, 2021, the CPC filed a comment letter regarding Health Canada’s “Drug-Device Combination Products (DDCPs) Draft for Consultation Issue Identification Paper.” The CPC appreciates Health Canada’s efforts to address the uniquely complex and challenging oversight required for drug-device combination products. CPC believes that global harmonization of certain standards for DDCPs across jurisdictions and streamlined approaches to minimize regulatory burdens would expedite access to innovative treatments for patients.  Among other specific recommendations, CPC encourages Health Canada to issue clear guidance documents regarding these important issues.